Table 2.
Patients' baseline characteristics
| Fluconazole group (n = 18) | Micafungin group (n = 18) | |
|---|---|---|
| Maternal fungal disorder at delivery (n) | 3 (17%) | 7 (39%) |
| Demographic data | ||
| Gender (M/F) | 11/7 | 11/7 |
| Gestational age (weeks + days) | 28 + 2 (24 + 1–40 + 1) | 26 + 6 (23 + 4–40 + 0) |
| Postnatal age (days) | 13.5 (2.0–101.0) | 12.5 (3.0–115.0) |
| Postmenstrual age (weeks) | 30.4 (25.6–49.1) | 29.9 (25.4–41.9) |
| Birth weight (g) | 995.0 (640.0–3960.0) | 885.0 (500.0–3630.0) |
| Current weight (g) | 1255.0 (750.0–4255.0) | 1090.0 (640.0–4615.0) |
| Patients with Candida isolates (n) | 10 (56%) | 7 (39%) |
| Positive peripheral cultures (n) | 19 | 9 |
| Positive blood/CSF cultures (n) | 1 | 0 |
| Biological data | ||
| Serum creatinine (μmol l–1) | 50.5 (12.0–138.0) | 43.0 (14.0–102.0) |
| Aspartate aminotransferase (IU l–1) | 21.0 (6.0–33.0) | 39.0 (21.0–1080.0) |
| Alanine aminotransferase (IU l–1) | 15.0 (6.0–43.0) | 13.0 (6.0–221.0) |
| Albumin (g l–1) | 30.0 (21.0–49.0) | 27.0 (14.0–36.0) |
| C‐reactive protein (mg l–1) | 15.0 (3.0–135.0) | 13.5 (3.0–225.0) |
| Haematocrit (%) | 42.8 (31.7–57.0) | 40.2 (25.2–50.8) |
| Clinical data | ||
| Invasive ventilation | 8 (44.4%) | 10 (55.6%) |
| Comedication | ||
| Aminoglycosides | 5 (27.8%) | 8 (44.4%) |
| Vancomycin | 9 (50.0%) | 12 (66.7%) |
| Inotropic agents | 6 (33.3%) | 7 (38.9%) |
| Diuretics | 2 (11.1%) | 4 (22.2%) |
| Caffeine | 9 (50.0%) | 8 (44.4%) |
Data represent median (range) or n (%). CSF, cerebrospinal fluid